Dermatology Times, August 2024 (Vol. 45. No. 08)

David Goldberg, MD, JD, stated the use of drugs and devices for conditions that are not otherwise indicated is widespread among physicians and is generally not considered experimental or investigational.

David Mandell, JD, MBA, stated in the quest to protect against malpractice liability, insurance is certainly the first and most important line of defense.

“This approval reflects our dedication to ensuring high-quality treatments are universally accessible,” Claire D’Abreu-Hayling, chief scientific officer of Sandoz, said in a news release.

Learn more about the OX40-OX40L pathway and 2 drugs heading toward phase 3 trials.

Zoe Draelos, MD, presents vignettes based on common hair problems that patients face, with possible dermatologic solutions.

To improve overall outcomes for patients with large basal cell carcinomas, it has been beneficial to employ the use of vismodegib as a neoadjuvant and/or adjuvant treatment.

Kristine Kucera, MPAS, PA-C, DHS, discusses her patient's challenging atopic dermatitis that was eventually cleared with upadacitinib.

Melasma, challenging due to varied pigmentation in different skin types, requires personalized, tailored care.

Young patients are heading back to school, and common skin issues like acne, eczema, warts, and pigmentation can affect their confidence, Shanna Miranti, MPAS, PA-C, writes.

Our August issue covers common back-to-school skin conditions, psoriasis research, OX40 inhibition for atopic dermatitis, and pediatric dermatology meeting highlights.

This week’s collection of the latest dermatologic studies includes oral dutasteride for frontal fibrosing alopecia, effects of air pollutants for patients with acne, bimekizumab in patients with PsA without methotrexate, and itepekimab for adults with moderate to severe AD.

A recent study reviewed the current evidence on the impact of key vitamins and minerals on rosacea and provided clinical recommendations.

This week’s collection of the latest dermatologic studies includes drug-induced epidermal necrolysis in pediatric patients, predicting relapse in chronic spontaneous urticaria, fatigue in patients with psoriasis and psoriatic arthritis, and the role of eosinophils in hidradenitis suppurativa.

Lisa Weibel, MD, delved into skin signs of systemic diseases in the first of 2 Hurwitz lectures to be presented at the SPD's annual meeting.

The average pain score reported during treatment was 0.4/10, according to a poster presented at the SPD's annual meeting.

Christopher Bunick, MD, PhD, provides insights into new research exploring bimekizumab’s unique binding to IL-17F and IL-17A by analyzing crystals of bimekizumab fragment antigen-binding.